Biological E

Vaxxed to the max: Two years on, India starts COVID-19 vaccination for 12-14 age group

The country's battle against the coronavirus pandemic began a new phase on Wednesday as children aged 12 to 14 years began to get their vaccine against the virus. Beneficiaries in this phase will receive Biological E's Corbevax vaccine

DCGI grants restricted EUA to Biological E's COVID-19 vaccine Corbevax for 12-18 age group

This is the third vaccine to have received EUA from the DCGI for the age group of 12-18 years after Zydus Cadila's ZyCoV-D and Bharat Biotech's Covaxin

Biological E's Corbevax booster trial to begin soon: 360 participants, 8 centres, 2 groups

The study will capture data – under the primary endpoints – virus neutralising antibodies against SARS-CoV-2 at baseline and again at 28 days post booster dose.

Narendra Modi meets Indian COVID-19 vaccine makers, lauds them for 'big role' in country's success

Representatives from seven vaccine makers — Serum Institute of India, Bharat Biotech, Dr Reddy's Laboratories, Zydus Cadila, Biological E, Gennova Biopharma and Panacea Biotech — participated in the meeting

Biological E seeks DCGI approval to conduct Phase 3 trials for Corbevax as booster dose for Covishield, Covaxin

Currently, phase 2/3 trials of the RBD protein sub-unit vaccine is underway and the results are likely to be declared this month.

Health ministry to buy 30 cr COVID-19 vaccine doses from Biological-E for Rs 1,500 cr

The vaccine recently got the nod of approval for phase-3 clinical trials after showing promising results in phase 1 and 2.

Centre finalises deal for 30 cr Biological-E COVID-19 vaccines, shots may be out in 'few months'

In April, the Hyderabad company had got the nod from the Central Drugs and Standards Control Organisation (CDSCO) to conduct phase 3 clinical trials on its Covid vaccine candidate, which it is developing in association with Baylor College of Medicine, US

Hyderabad-based Biological E to manufacture Canadian firm Providence's COVID 19 vaccine

Biological E will conduct a bridging trial for the vaccine in India and also manufacture the vaccine.

Biological E to produce 600 mn doses of Johnson & Johnson COVID-19 vaccine a year:

Interim data for Biological E's own COVID-19 vaccine, still in clinical trials, is expected later this quarter.

SII rejects Covishield volunteer's allegations; PM to interact with 3 teams making COVID vaccine today

A 40-year-old man who took part in the 'Covishield' vaccine trial in Chennai has alleged serious side effects, including a virtual neurological breakdown and impairment of cognitive functions and has sought compensation of Rs 5 crore